Disclosures for "Efficacy and Safety of LTG-001, a Selective NaV1.8 Inhibitor, in Patients with Moderate to Severe Pain after Abdominoplasty"
-
Dr. Singla has received personal compensation for serving as an employee of Latigo Biotherapeutics. Dr. Singla has received personal compensation for serving as an employee of Evolution Research Group. Dr. Singla has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Singla has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Tris Pharma. Dr. Singla has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Becton Dickinson. Dr. Singla has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for Evolution Research Group. Dr. Singla has or had stock in Evolution Research Group. An immediate family member of Dr. Singla has or had stock in The Marigold Center (Private Practice).
-
Author has nothing to disclose
-
Dr. Minkowitz has nothing to disclose.
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Mr. Rogier has received personal compensation for serving as an employee of Latigo Biotherapeutics. Mr. Rogier has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Latigo Biotherapeutics. Mr. Rogier has received personal compensation in the range of $0-$499 for serving as a Consultant for Evolution Research Group.